Humanitarian Madhusudan Sai awarded Fiji's highest honour
In a press release issued by the Sri Madhusudan Sai Institute of Medical Sciences and Research, Chikkaballapura, Sai stated: 'This honour is a testament to the collective efforts of so many who have worked tirelessly to uplift and support communities across the country as well as the entire Pacific region.' According to the press release, Sai was conferred the award for establishing the Sri Sathya Sai Sanjeevani Children's Hospital in Fiji.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Biocon sees GLP-1 weight-loss therapy as a future growth driver
Synopsis Biocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 India launch. CEO Shreehas Tambe said both portfolios are complementary. Biocon aims to leverage its insulin experience for GLP-1 success, following US FDA approval for insulin aspart and India approval for liraglutide. External risks remain a key concern. ET Bureau Biocon will continue to deepen its push in the insulin business, even as the biopharmaceutical company will have GLP-1 weight-loss therapy as one of the key focus areas in its future growth strategy, Shreehas Tambe, chief executive of Biocon Biologics, told ET on decades of experience in insulin, the Bengaluru-based company aims to gain an edge over rivals in the race for copycats of GLP-1 drugs, which are gaining popularity as an effective treatment for glucose control as well as weight management. Biocon has completed bioequivalence studies in India for semaglutide, a GLP-1 drug, and is progressing to Phase-III trials, which it expects to conclude by the end of calendar year 2026.'Subsequent regulatory approval is anticipated in CY 2027, after which we will launch the product in India through a partner,' said Tambe, who is also the managing director of the biosimilar and biologics subsidiary of Nordisk's blockbuster weight-loss drug semaglutide (branded Wegovy) will go off patent in India in March. On being asked about the disruption in the diabetes drug segment due to the inroads by GLP-1 products, Tambe said: 'The disruption (due to GLP-1) is complementary to insulin. We are bullish on both insulin and GLP-1.''The originators who brought GLP1s are the insulin companies, and they were able to do that because it is synergistic. Synergy not just in terms of the therapy area but also in terms of operations, touchpoints for prescribers, healthcare givers and customers,' said Tambe, who is also the company's managing has both biosimilar insulins and GLP-1 peptides that mimic a naturally occurring gut hormone that controls sugar levels and appetite. 'That is what differentiates us from the rest,' he said.'Having been close to the market will give an advantage because it requires a lot of expertise as the drug is in the form of an injectable, given in a device, is a chronic treatment and hence requires a long-term relationship with patients who need to be trained on those devices,' said Tambe. 'All of these we have been able to do with our insulins in the past several years in 80-plus countries that is why we feel confident and we are developing both portfolios that are complementary to each other.'The company got US Food and Drug Administration approval for insulin aspart, its second interchangeable biosimilar insulin, deepening its presence in the US insulin market.'The US FDA approval of Kirsty (biosimilar aspart) builds on the strong foundation established with Semglee (biosimilar insulin glargine), enabling us to offer patients the full range of affordable short- and long-acting insulin therapies,' he said. 'Insulin aspart we will enter by the end of this fiscal,' he company got approval for diabetes drug liraglutide in India in June. The drug, used in treating type-2 diabetes, has already launched in the UK and the EU.'We are working towards expeditiously launching the drug product through our commercialisation partners in India,' said Tambe.'The biggest concern for the year ahead is external risks to the business, such as potential tariff and geopolitical headwinds. Some of these things are not in our control but that is the biggest concern for the whole industry too,' he said.
Time of India
2 hours ago
- Time of India
Biocon sees GLP-1 weight-loss therapy as a future growth driver
Biocon will continue to deepen its push in the insulin business, even as the biopharmaceutical company will have GLP-1 weight-loss therapy as one of the key focus areas in its future growth strategy, Shreehas Tambe, chief executive of Biocon Biologics, told ET on Friday. Leveraging decades of experience in insulin, the Bengaluru-based company aims to gain an edge over rivals in the race for copycats of GLP-1 drugs, which are gaining popularity as an effective treatment for glucose control as well as weight management. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Biocon has completed bioequivalence studies in India for semaglutide , a GLP-1 drug, and is progressing to Phase-III trials, which it expects to conclude by the end of calendar year 2026. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 'Subsequent regulatory approval is anticipated in CY 2027, after which we will launch the product in India through a partner,' said Tambe, who is also the managing director of the biosimilar and biologics subsidiary of Biocon. Novo Nordisk's blockbuster weight-loss drug semaglutide (branded Wegovy) will go off patent in India in March. Live Events On being asked about the disruption in the diabetes drug segment due to the inroads by GLP-1 products, Tambe said: 'The disruption (due to GLP-1) is complementary to insulin. We are bullish on both insulin and GLP-1.' 'The originators who brought GLP1s are the insulin companies, and they were able to do that because it is synergistic. Synergy not just in terms of the therapy area but also in terms of operations, touchpoints for prescribers, healthcare givers and customers,' said Tambe, who is also the company's managing director. Biocon has both biosimilar insulins and GLP-1 peptides that mimic a naturally occurring gut hormone that controls sugar levels and appetite. 'That is what differentiates us from the rest,' he said. 'Having been close to the market will give an advantage because it requires a lot of expertise as the drug is in the form of an injectable, given in a device, is a chronic treatment and hence requires a long-term relationship with patients who need to be trained on those devices,' said Tambe. 'All of these we have been able to do with our insulins in the past several years in 80-plus countries that is why we feel confident and we are developing both portfolios that are complementary to each other.' The company got US Food and Drug Administration approval for insulin aspart, its second interchangeable biosimilar insulin, deepening its presence in the US insulin market. 'The US FDA approval of Kirsty (biosimilar aspart) builds on the strong foundation established with Semglee (biosimilar insulin glargine), enabling us to offer patients the full range of affordable short- and long-acting insulin therapies,' he said. 'Insulin aspart we will enter by the end of this fiscal,' he said. The company got approval for diabetes drug liraglutide in India in June. The drug, used in treating type-2 diabetes, has already launched in the UK and the EU. 'We are working towards expeditiously launching the drug product through our commercialisation partners in India,' said Tambe. 'The biggest concern for the year ahead is external risks to the business, such as potential tariff and geopolitical headwinds. Some of these things are not in our control but that is the biggest concern for the whole industry too,' he said.
India.com
3 hours ago
- India.com
Meet woman, married to Indian billionaire who had Rs 200000000000 net worth, but sold his Rs 12000 crore company for just Rs 74 due to...
Chandrakumari Shetty is the wife of embattled former billionaire BR Shetty. (File) Dr. Chandrakumari Shetty, the wife of disgraced Indian-born billionaire Dr. BR Shetty, established the New Medical Center Health (NMC)– the first private healthcare provider in the UAE– in Dubai in 1975. During its initial years, Chandrakumari was the only doctor at the hospital and managed the entire facility by herself. However, NMC has grown into the UAE's largest private healthcare provider today, with over four million patients annually across its 45 facilities spread over 12 cities and 8 countries, including UAE, KSA, Oman, Spain, Italy, Denmark, Colombia, and Brazil. Who is BR Shetty? Bavaguthu Raghuram Shetty, or BR Shetty as he is popularly known, was born in a middle-income home in Udupi, Madras Presidency, then British India (now Karnataka, India), on August 1, 1942, and at the age of 31, immigrated to the Dubai in 1973 in search of better opportunities. According to media reports, BR Shetty, who started his career as a medical representative, arrived in Dubai with just $8 to his name, and began working as a door-to-door salesman, selling medicines. However, within a brief span of time, Shetty developed contacts with several wealthy and influential people, and a few years later, established UAE's first private healthcare provider, New Medical Center Health (NMC), in Dubai. was once counted among the wealthiest people on the planet, ranking on the Forbes list of India's 100 Richest People in 2015, and the 42nd richest person in 2019. What led to BR Shetty's downfall? After establishing NMC, BR Shetty started to diversify his businesses and investments, ranging from health, finance, to real estate, and capital investment. Shetty's successful business ventures resulted in him amassing a large, and at one point, he had a net worth of $3 billion (around Rs 20,000 crore), earning him a spot on the Forbes list of India's 100 Richest People in 2015, and the 42nd richest person in 2019. The Indian-born business tycoon lived a life of opulence, owned private jets and a fleet of Rolls Royce vehicles, and even bought two entire floors in the lavish Burj Khalifa, besides several luxurious villas across Dubai. However, destiny had a cruel fate in store for BR Shetty, when in 2019 , Muddy Waters Research levelled damning allegations against his companies. In a post on X (former Twitter), the US-based short-seller posted a report revealing that Shetty's firm owed a $1 billion debt which was kept secret from the company's investors. In its report, Muddy Waters Research alleged that Shetty had hid the debt from his investors and defrauded them by exaggerating cash flow figures. Following the allegations, the shares of Shetty's companies went into freefall, ultimately forcing him sell his Rs 12,478 crore company to the Israel-UAE consortium for just Rs 74. Who is Chandrakumari Shetty? Dr. Chandrakumari Shetty, the wife of embattled Dubai-based Indian billionaire BR Shetty, is a trained medical doctor by profession, who along with her husband, established the NMC, UAE's first private healthcare provider, which has today grown into a healthcare giant with 45 facilities spread over 12 cities and 8 countries, including UAE, KSA, Oman, Spain, Italy, Denmark, Colombia, and Brazil. Under Chandrakumari Shetty's leadership, NMC Health grew into the largest private healthcare company in the UAE, but following her husband's bankruptcy, she stepped down from her leadership role in the company in 2021, citing personal reasons.
